leisure time -WSS

leisure time

author：explore 2025-08-11 07:59:16 - browse：14

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： With trial win, GSK could get blood cancer drug back on market

WSS

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

See how much Covid

How to increase colonoscopy rates? Looks like an AI can help

New weight loss drugs vying to be the next Wegovy or Mounjaro

Change Healthcare can notify patients about the breach, HHS says

FDA panel endorses Alnylam’s heart drug — after picking it apart

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA's Pazdur wants cancer trials to range beyond China alone

What does generative AI mean for health care? We asked experts

ASCO: AstraZeneca says CAR

Hollywood unions extend contract negotiations for actors

Long Covid needs a new name — and a new frame

The cancer drug shortage isn’t new — and neither are the solutions

How to make the FDA’s new prescription one

Medical records are filled with copy

Regeneron agrees to White House price limits on anti

hotspot

WATCH: Why do bright lights make us see spots?

FDA approves updated Covid vaccines

Generate Biomedicines machine learning biotech raises $273M

ASCO: AstraZeneca says CAR

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Telehealth for opioid use disorder is lifesaving

hotspot

focus

focus

entertainment